Abstract:AbstractBackgroundRecent studies have shown that almost half of patients with Alzheimer’s disease demonstrate signs of epileptic activity as measured with EEG. Subclinical epileptic discharges can disrupt network activity, which is critical for long term memory. Therefore, suppressing epileptiform discharges may represent a novel therapeutic target for patients with Alzheimer’s disease. In the current randomized controlled trial, we recruited patients with mild Alzheimer’s disease and investigated the effect of a single administration of 2.5 mg/kg or 7.5 mg/kg of levetiracetam as compared with placebo on cerebral blood flow as measured with arterial spin‐labeling MRI (ASL‐MRI).MethodWe conducted a double‐blind, within‐subject crossover study in which nine participants with mild Alzheimer’s disease received placebo, 2.5 mg/kg, and 7.5 mg/kg of LEV intravenously in a randomized order across three sessions. Afterwards, participants underwent ASL‐MRI and performed a variety of neuropsychological cognitive tests. The regions with significant perfusion changes were analyzed with Statistical nonParametric Mapping (SnPM) toolbox.ResultWhen comparing 2.5 mg/kg levetiracetam with placebo, we found significant (p<0.03 with family wise error corrected at a level of 0.05) increases in relative cerebral blood flow in a cluster involving both temporal lobes, including the hippocampus, with greater involvement on the left side. We found decreases in a cluster including the posterior cingulate cortex and precuneus. No clear changes were found following the higher dose. No significant differences in cognitive performance were found between the three groups, suggesting that the intervention neither worsened nor improved cognition.ConclusionIn the current study, we found that in mild Alzheimer’s disease patients without any history of epilepsy a low dose of levetiracetam leads to changes in the cerebral blood flow in areas known to be affected early in the disease. One possible explanation could be that in mild AD, epileptic activity in the hippocampus leads to an excessive inhibition, and so relieving the inhibition with levetiracetam leads to an increased blood flow. These findings provide evidence of a potential beneficial effect of levetiracetam in patients with Alzheimer’s disease, but larger studies are needed, particularly with longer dosage schedules to determine whether there are any clinical improvements.

Oligoprotective Activity of Levetiracetam Against Glutamate Toxicity: An in vitro Study

A Randomized Controlled Trial Measuring Changes in Cerebral Blood Flow after Levetiracetam in Patients with Alzheimer’s Disease

Levetiracetam inhibits oligomeric Aβ-induced glutamate release from human astrocytes

Impact of levetiracetam on cognitive impairment, neuroinflammation, oxidative stress, and neuronal apoptosis caused by lipopolysaccharides in rats

Therapeutic Effect of Levetiracetam Against Thioacetamide-Induced Hepatic Encephalopathy Through Inhibition of Oxidative Stress and Downregulation of NF-κB, NLRP3, iNOS/NO, Pro-Inflammatory Cytokines and Apoptosis

Effect of levetiracetam on DNA oxidation and glutathione content in a temporal lobe epilepsy model

Levetiracetam promoted rat embryonic neurogenesis via NMDA receptor-mediated mechanism in vitro

Levetiracetam Administration is Correlated with Lower Mortality in Patients with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes: a Retrospective Study

Effect of Levetiracetam on Oxidant–Antioxidant Activity during Long-Term Temporal Lobe Epilepsy in Rats

Modulation of action potential and calcium signaling by levetiracetam in rat sensory neurons

Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients

Levetiracetam Ameliorates Doxorubicin-Induced Chemobrain by Enhancing Cholinergic Transmission and Reducing Neuroinflammation Using an Experimental Rat Model and Molecular Docking Study

The anticonvulsant activity and cerebral protection of chronic lithium chloride via NMDA receptor/nitric oxide and phospho-ERK

Brivaracetam and Levetiracetam Suppress Astroglial L-Glutamate Release through Hemichannel via Inhibition of Synaptic Vesicle Protein

Levetiracetam Protects Against Cognitive Impairment Of Subthreshold Convulsant Discharge Model Rats By Activating Protein Kinase C (Pkc)-Growth-Associated Protein 43 (Gap-43)-Calmodulin-Dependent Protein Kinase (Camk) Signal Transduction Pathway

Neuroprotective Effects of Albizia lebbeck (L.) Benth. Leaf Extract against Glutamate-Induced Endoplasmic Reticulum Stress and Apoptosis in Human Microglial Cells

Effects of Levetiracetam As an Add-on Therapy on Cognitive Function and Quality of Life in Patients with Refractory Partial Seizures

Levetiracetam prevents Aβ42 production through SV2a-dependent modulation of App processing in Alzheimer's disease models

A Mitochondrial Role of SV2a Protein in Aging and Alzheimer's Disease: Studies with Levetiracetam

Enhancement of Glutamate Uptake as Novel Antiseizure Approach: Preclinical Proof of Concept

Levetiracetam inhibits endocytosis and augments short-term depression